Background: Antiretroviral therapy is associated with metabolic complications, including dyslipidaemia, body fat changes and insulin resistance. Healthy volunteer studies have demonstrated a decrease in glucose disposal associated with dosing with specific antiretrovirals. Methods: HIV-type-1-positive male participants were randomized to receive tenofovir disoproxil fumarate and lamivudine, with either fosamprenavir (FPV)/ritonavir or lopinavir (LPV)/ritonavir twice daily. A hyperinsulinaemic euglycaemic clamp was performed at baseline and at 2 weeks after commencing treatment. The homeostasis model assessment index for insulin resistance (HOMA-IR) was also calculated at these time points. Changes in lipids and lipoprotein subfractions (by nuclear magnetic resonance spectroscopy) were assessed. A pharmacokinetic assessment was undertaken at week 2. Results: A total of 27 participants were enrolled. There was no significant change in whole-body insulin sensitivity or HOMA-IR from baseline or between groups. Total cholesterol increased significantly, by 6.6% with FPV and 10.9% with LPV. The changes in lipids and lipoprotein subfractions were similar between groups with increases in triglycerides, very low-density lipoprotein (VLDL) and chylomicrons, and low-density lipoprotein (LDL) particles. Although the total high-density lipoprotein (HDL) particles were not significantly altered, a decrease in small HDL particles was seen. Changes in VLDL and chylomicron particles in both groups and triglycerides and small HDL particles in the LPV group were statistically significant. Conclusions: In HIV-type-1-positive men initiating antiretroviral therapy with FPV-or LPV-based regimens, there were no significant changes in whole-body insulin sensitivity after 2 weeks. A proatherogenic lipid profile characterized by increases in triglycerides, VLDL and chylomicron particles and LDL particles, and a decrease in small HDL particles, was observed in both groups.
Specific antiretrovirals are known to be associated with the development of metabolic and morphological abnormalities, including insulin resistance, dyslipidaemia and body fat changes [1] . The effect of different antiretrovirals on peripheral glucose disposal and insulin sensitivity has been investigated using the hyperinsulinaemic euglycaemic clamp [2] , which is the gold standard for investigating glucose homeostasis in a research setting. These studies have been generally performed in healthy volunteers in an attempt to isolate the effect of individual drugs. Reductions in insulin sensitivity have been seen in these studies, with drugs from both the protease inhibitor [3] [4] [5] [6] [7] and nucleoside reverse transcriptase inhibitor (NRTI) classes [8, 9] . In the Multicenter AIDS Cohort Study, HIV infection (regardless of treatment status) was associated with decreased insulin sensitivity as measured by the quantitative insulin sensitivity check index. Cumulative exposure to NRTIs, but not protease inhibitors, was associated with insulin resistance [10] .
The aim of this study was to investigate the effect of commencing two different antiretroviral combinations on the glucose metabolism of HIV type-1 (HIV-1)-positive male patients, who were treatment-naive, and to determine whether any observed changes in whole-body insulin sensitivity correlated with specific Introduction changes in virological, immunological or pharmacokinetic parameters. The hyperinsulinaemic euglycaemic clamp was utilized as the primary measure of the effect of these drug combinations on glucose homeostasis. Changes in lipid parameters (including lipoprotein subfractions, assessed by nuclear magnetic resonance [NMR] spectroscopy) were also assessed.
Methods

Study design
This was a single-centre open-label study. Treatmentnaive HIV-1-positive male patients were enrolled from the HIV outpatient unit at Chelsea and Westminster Hospital (London, UK). Patients were randomized (1:1) to receive either fosamprenavir (FPV)/ritonavir (700 mg/100 mg twice daily) or lopinavir (LPV)/ ritonavir (400 mg/100 mg twice daily) with lamivudine 300 mg once daily and tenofovir disoproxil fumarate 300 mg once daily. Two hyperinsulinaemic euglycaemic clamp procedures were performed: at baseline, prior to the commencement of antiretroviral therapy, and 14 days later. In addition, the homeostasis model assessment index for insulin resistance (HOMA-IR) [11] was calculated at each time point using the following formula: (fasting insulin [mU/l]× fasting glucose [mmol/l])/22.5. At the second clamp, blood samples were taken for pharmacokinetic evaluation. In addition to the blood samples taken to evaluate safety, fasting samples were taken for assessment of lipid parameters. Contact was made with the study participants 1 week after completion of the clamps for further evaluation of adverse events.
Eligibility criteria
The study was approved by the Southampton and South West Hampshire Research Ethics Committee (Reading, UK) and conducted according to the principles of Good Clinical Practice. Participants gave informed consent and were screened up to 45 days prior to their baseline visit. Participants were included if they were aged 18-60 years, and were clinically well, naive to antiretroviral therapy (<4 weeks cumulative exposure to any previous antiretroviral regimen) and not receiving any metabolically active medication. Fasting metabolic parameters were required to be below the upper limit of normal: glucose <6.0 mmol/l (108 mg/dl); triglycerides <2.0 mmol/l (177 mg/dl) and cholesterol <5.0 mmol/l (193 mg/dl). Screening cutoffs for cholesterol were based on the Joint British Societies' guidelines on the prevention of cardiovascular disease in clinical practice [12] . Important exclusion criteria included waist:hip ratio <0.97, body mass index >28 kg/m 2 , acute or chronic hepatitis B or C, diabetes mellitus, active opportunistic disease or wasting syndrome, and any disease process likely to cause a marked disturbance in glucose and lipid homeostasis.
Hyperinsulinaemic euglycaemic clamp
Participants were admitted to the research unit after an overnight fast of at least 8 h. An intravenous cannula was inserted into the right antecubital fossa for infusion of insulin and a 20% glucose solution. A retrograde cannula, was inserted in the back of the distal third of the left forearm, which was heated to 55°C in a thermoregulated box. This was used for blood sampling for the duration of the 180 min hyperinsulinaemic euglycaemic clamp procedure. At time (t)=0, a continuous infusion of insulin (100 IU/ml; Actrapid ® ; Novo Nordisk A/S, Bagsvaerd, Denmark) was commenced at 80 mU/ m 2 /min. At t=5 min, the rate was reduced to 60 mU/m 2 /min until t=10 min, when it was reduced to 40 mU/m 2 /min and continued at this rate for the remainder of the clamp. At t=4 min, the 20% glucose solution was commenced, and, from t=10 min, the plasma glucose was analysed (i-STAT ® Analyser; iSTAT Corporation, East Windsor, NJ, USA) every 5 min. A negative feedback formula was used to adjust the rate of glucose infusion in order to maintain euglycaemia at 4.5 mmol/l. Serial electrocardiogram and whole-blood potassium during the course of the clamp was checked, in order to monitor for the development of hypokalaemia. Blood samples were taken at t=120, 150 and 180 min to determine average insulin concentration during the last hour of the clamp. Whole body insulin sensitivity was assessed by calculating the glucose disposal rate (M) during the last hour of the clamp divided by the mean insulin concentration (I) over this time, to obtain the ratio of M/I.
Pharmacokinetic analyses
At the week-2 visit, blood samples for pharmacokinetic evaluation were taken. A predose sample was taken prior to a witnessed dose of antiretrovirals, which was administered at t=0, marking the commencement of the clamp. A 6-h pharmacokinetic curve was determined, with samples taken at t=120, 180, 240, 300 and 360 min for concentrations of ritonavir, and amprenavir (APV) or LPV. APV, LPV and ritonavir plasma concentrations were measured by HPLC-tandem mass spectrometry, as previously described [13] .
Lipoprotein subfraction
NMR spectroscopy was used to investigate the changes in lipoprotein particle number and size after commencing treatment. Samples were processed by Esoterix Clinical Trial Services (Mechelen, Belgium).
Statistical analyses
This was a pilot study to evaluate for differences in metabolic parameters after commencing two different antiretroviral combination therapies in an HIV-1-positive population. As such, there were limited data on which to base a formal power calculation. We planned to recruit up to 32 patients to achieve a target of 12 evaluable patients per treatment arm. Comparison of primary and secondary outcome measures was performed using non-parametric statistical tests, namely the Wilcoxon signed-rank test for changes from baseline and the Mann-Whitney U test for intergroup differences. Linear regression analysis was also utilized to examine relationships between changes in insulin sensitivity and changes in immunological, virological and pharmacokinetic parameters. All statistical analyses were performed using SPSS version 16 (SPSS Inc., Chicago, IL, USA).
Results
A total of 27 patients were enrolled and randomly allocated by a sealed envelope to the treatment arms; 15 patients received LPV/ritonavir-and 12 received FPV/ritonavir-based regimens. Baseline parameters and changes 2 weeks after commencing treatment are presented in Table 1 .
There was no significant difference in whole-body insulin sensitivity from baseline after 2 weeks of treatment or between groups, as assessed by M/I, which was derived from the clamp procedure. The median percentage change (interquartile range [IQR] ) from baseline to week 2 in M/I was -1.45% (-10.83-5.34) in the FPV arm and -8.41% (-18.60-16.51) in the LPV arm. Intraindividual changes are shown in Figure 1 . In order to evaluate the glucose level achieved over the last hour of the procedure (t=120-180 min), the mean ±sd glucose value over this period was calculated for each patient. The overall mean ±sd glucose value was 4.48 mmol/l ±0.06 and the mean ±sd of the standard deviations was 0.28 ±0.14. The HOMA-IR was also not significantly altered between visits and between groups (Table 1) .
Baseline and changes 2 weeks after commencing antiretrovirals in lipid parameters are presented in Table 2 . Statistically significant increases in total cholesterol were seen in both groups, whereas triglycerides were also significantly increased in the LPV arm. Median (IQR) percentage increases in total cholesterol were 5.5% (2.0-11.6) and 8.3% (2.9-11.6) in the FPV and LPV arms, respectively. The median (IQR) changes after 2 weeks of treatment in the lipoprotein subfractions for the FPV versus LPV arms, respectively, were 18 2) for HDL. There were no significant intergroup differences. In addition, mean particle size was not significantly affected (PAR et al., data not shown).
The increase in total VLDL and chylomicron particles from baseline was statistically significant (P=0.041 for the FPV arm and P=0.012 for the LPV arm) and predominately related to a significant increase in medium VLDL particles in both groups (Figure 2A) . The trend towards an increase in total LDL particles did not reach statistical significance (P=0.249 for the FPV arm and P=0.065 for the LPV arm), with the increase being spread across all of the LDL subfractions ( Figure 2B ). Although the total HDL particles were not significantly altered after 2 weeks of treatment, there was a change in the pattern of lipoprotein subfractions with a significant increase seen in the medium HDL particles (P=0.012 for the FPV arm and P=0.001 for the LPV arm). The decrease seen in the small HDL particles (Figure 2C ) was only statistically significant in the LPV arm (P=0.041 versus P=0.272 in the FPV arm). In the LPV arm (n=15), the median (range) area under the curve (AUC), maximum plasma concentration (C max ) and minimum plasma concentration (C min ) of LPV were 35,784 ng/ml•h (14,988-64,006), 7,476 ng/ml (4,687-12,662) and 4,561 ng/ml (195-8,925), respectively. In the FPV arm (n=9), the median (range) AUC, C max and C min of APV were 15,277 ng/ml•h (10,475-19,610), 4,120 ng/ml (2,970-5,148) and 1,328 ng/ml (638-2,244), respectively. The full 6-h pharmacokinetic evaluation was not available for 3 of 12 patients in the FPV arm and they were therefore not included in the statistical evaluation. Two patients in the FPV arm and Outermost data are median (interquartle range) for overall within-group analysis. Data in the middle of each plot represents intraindividual change. There was no statistically significant change from baseline to week 2 in either group. Median percentage change in the ratio of glucose disposal rate during the last hour of the clamp to the mean insulin concentration (M/I) was -1.45% in the fosamprenavir (FPV) arm and -8.45% in the lopinavir (LPV) arm. one in the LPV arm had C min values for the respective protease inhibitor that were below the suggested minimum effective concentration defined as 700 ng/ml for APV and 1,000 ng/ml for LPV [14] . Ritonavir exposure was significantly higher in the FPV arm. Median (range) ritonavir pharmacokinetic parameters for the FPV versus LPV arms were 2,970 ng/ml•h (1,443-5,759) versus 1,427 ng/ml•h (580-2,775) for AUC (P=0.004), 849 ng/ml (337-1,154) versus 330 ng/ml (186-538) for C max (P=0.001) and 201 ng/ml (88-474) versus 144 ng/ ml (<29-313) for C min (P=0.219). There was no significant correlation between M/I and antiretroviral drug levels, changes in lipid parameters, CD4 + T-cell count or changes in CD4 + T-cell count. There were no serious adverse events experienced by study participants and no grade 3-4 adverse events. The most common adverse event reported during the study was diarrhoea, with 4 of 12 patients in the FPV arm and 9 of 15 patients in the LPV arm experiencing ≥1 episode.
Discussion
In this study, we investigated the effect of initiating two ritonavir-boosted protease-inhibitor-based antiretroviral regimens, FPV and LPV, both with tenofovir disoproxil fumarate and lamivudine, on glucose and lipid homeostasis in HIV-1-positive male patients. After 2 weeks of treatment, there was no significant effect on whole-body insulin sensitivity, as assessed by the hyperinsulinaemic euglycaemic clamp or by HOMA-IR. In our patients, changes in lipids and lipoprotein particles were similar between groups, with a trend towards an atherogenic profile characterized by increases in triglycerides, VLDL and chylomicron, and LDL particles, and a decrease in small HDL particles.
The effect of different protease inhibitors on insulin sensitivity has been investigated in a number of volunteer studies with single and multiple doses over varying lengths of time [4, 6, 7, [15] [16] [17] [18] . Clearly, comparisons across studies performed by different investigators employing different methods for assessing changes in insulin sensitivity are difficult. However, it appears that in healthy volunteers protease inhibitors have variable effects on glucose homeostasis with any reduction in insulin sensitivity most apparent acutely (within the first 14 days of initiation of treatment). The effect of LPV/ritonavir has been extensively investigated with 5 [16] and 10 [7] days of dosing, resulting in an approximate 25% reduction in the glucose disposal rate, whereas 2 weeks of dosing led to a 16.1% reduction [17] . Interestingly, 4 weeks of dosing with LPV/ritonavir did not significantly affect insulin sensitivity [4, 18] . NRTIs have also been implicated in the development of insulin resistance [8] [9] [10] 19, 20] , and the NRTI backbone used in this study was selected as one likely to have a minimal metabolic effect. The effect of tenofovir disoproxil fumarate on glucose metabolism has been investigated using the hyperinsulinaemic euglycaemic clamp in healthy volunteers, with no significant changes seen in insulin sensitivity [21] .
Because our study investigated potential changes over a short period of time, we had anticipated that there might have been a reduction in whole-body insulin sensitivity, as observed in volunteer studies of similar length. Studies looking at HIV-positive participants over the longer term [8, [22] [23] [24] have not demonstrated the short-term effects of protease inhibitors on insulin sensitivity seen in HIV-negative volunteers, and a recently published study [25] , showing that 24 months of an NRTI-sparing LPV-based regimen does not result in a deterioration in glucose metabolism, has further called into question the notion that protease inhibitors (certainly LPV) significantly contribute to the development of insulin resistance in HIV-positive individuals.
Although the results of our study are consistent with this view, an alternative hypothesis might also explain the lack of short-term effects observed. The reduction in the viral inflammatory burden resulting from the commencement of antiretroviral therapy might be responsible for counteracting any short-term effects of the protease inhibitors. HIV infection is associated with an abnormal cytokine response, including an increase in the proinflammatory cytokines, such as interleukin-6 and tumour necrosis factor-α [26] . These cytokines also contribute to the pathogenesis of insulin resistance [27] . We looked for a correlation between viral load decrease and changes in insulin sensitivity to further support our hypothesis, but no significant correlation was found (PAR et al., data not shown). Tissue concentrations of inflammatory cytokines and a longer period of follow-up would have been useful in order to further evaluate this hypothesis.
In addition to the assessment of total cholesterol, triglycerides, and LDL and HDL cholesterol, NMR spectroscopy [28] has been used to quantify the number and size of the different lipoprotein particles in an attempt to improve cardiovascular risk assessment [29] . In the Multicenter AIDS Cohort Study, antiretroviral therapy use in HIV-1-positive men was associated with the development of an 'atherogenic lipoprotein phenotype', which was characterized by an increase in triglycerides, VLDL and small LDL particles, and a decrease in large LDL and HDL particles [30] . Although data from the SMART study suggested that treatment interruption was associated with a reduction in HDL particles and that HDL particle concentration (particularly large and small HDL particles), and not LDL particle concentration, predicted cardiovascular disease events in HIV-positive patients [31] . The lipid changes seen in the present study are likely to represent more than a 'restoration to health' and it would be important to investigate these changes over a longer period of follow-up to establish the significance and contribution to cardiovascular risk. It is also important to consider a number of potentially confounding factors. The NRTI backbone included tenofovir disoproxil fumarate, which has been associated with modest reductions in total and LDL cholesterol [21] . Another issue to consider is the potential effect of the boosting dose of ritonavir, particularly as newer protease inhibitors are coprescribed with lower ritonavir doses. In healthy volunteers, there is a correlation between ritonavir exposure and changes in lipid parameters [32] , and the addition of lopinavir to low-dose ritonavir resulted in further increases in total and HDL cholesterol [33] . Ritonavir exposure was significantly higher in the FPV arm, consistent with previously reported protease inhibitor interactions with ritonavir [34] . However, there was no correlation between lipid changes and ritonavir exposure in our study, suggesting that there is no additional effect of ritonavir (over and above that caused by the coadministered protease inhibitor) in inducing lipid changes. The finding that the increase in triglycerides and decrease in small HDL particles was only statistically significant in the LPV arm might be partly a result of the larger sample size in this arm and consequent narrower confidence intervals.
The limitations of this study include the relatively small sample size, single-centre follow-up, lack of female participants, as well as the short period of study, and it would be important to investigate the effect of longer treatment periods on glucose and lipid metabolism. In addition, the lower median baseline CD4 + T-cell count in the LPV arm might account for some of the differences between groups. It would also have been useful to measure C-peptide levels during the clamp procedure to confirm that the participants were fasted; consequently, endogenous insulin secretion cannot be completely ruled out. The intraindividual variability, small sample size and lack of controlling for factors such as smoking and exercise status might limit our ability to demonstrate small changes in insulin sensitivity. However, the study methodology would allow for clinically significant changes of the magnitude seen in volunteer studies to be demonstrated.
In conclusion, 2 weeks of treatment with lamivudine, tenofovir disoproxil fumarate and FPV/ritonavir or LPV/ritonavir in HIV-1-positive male patients did not significantly affect insulin sensitivity as assessed by the euglycaemic hyperinsulinaemic clamp and HOMA-IR. In addition, changes in lipoprotein subfractions assessed by NMR spectroscopy were described. Changes in lipids and lipoprotein subfractions were similar between arms, with significant increases in total cholesterol and a trend towards an atherogenic lipoprotein profile. Triglycerides were also significantly increased in the LPV arm.
